Ortiz 2002.

Methods	Design: parallel group randomized trial Duration of study: 2000 Follow‐up: 21–30 days
Participants	Country: Peru Setting: not reported Age: 4–11 years (mean 7.9 years) Sex: not reported Number included in study: 210 Inclusion criteria: aged 2–11 years with eggs of A lumbricoides,T trichiura,or Hymenolepis nana in a faecal sample Exclusion criteria: not reported Lost at follow‐up: 22 (10.5%) Number positive for A lumbricoides: 70 Number included in review: 63
Interventions	Treatment strategy: screening and treat the positive Group 1: nitazoxanide 100 mg/5 mL (2–3 years of age), 200 mg/10 mL (4–11 years of age) in the morning and evening for 3 consecutive days with food (n = 28) Group 2: albendazole single 10 mL dose of 200 mg/5 mL suspension (n = 35) Group 3: praziquantel 25 mg/kg/dose, 600 mg tablets (not included)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rates, pre‐ and post‐treatment GM epg, ERR, adverse events Outcomes not included in review: anthelmintic efficacy for Trichuris and Hymenolepis; efficacy of praziquantel for A lumbricoides
Notes	Diagnostic technique: Kato‐Katz Funding support: Romark Laboratories (Tampa, Florida, USA) provided the nitazoxanide suspension and gave financial support.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "the children were randomized to treatment with either nitazoxanide suspension or the comparator drug."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Different treatment schedule.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Details not reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	22 (10.5%) participants lost at follow‐up, dropouts not balanced among groups and not included in analysis.
Selective reporting (reporting bias)	Low risk	All stated outcome were reported.
Other bias	Unclear risk	Financial support by Romark laboratories.